Study designs
³A multicenter, open-label, prospective study was undertaken in MMF-treated renal transplant patients including patients experiencing GI complaints were converted to equimolar EC-MPS (Cohort A, n=177) and patients without GI complaints remained on MMF (Cohort B, n=101), to determine if patients with GI complaints who are converted from MMF to EC-MPS experience improvements in GI symptom severity and HRQoL; and to evaluate the impact of GI symptoms on patients’ perceptions of symptom severity, GI-specific HRQoL, and general HRQoL.
⁴A retrospective study comparing MMF and EC-MPS in all consecutive kidney transplants (n=1,709) between 2000 and 2006 was conducted to determine whether there was a clinically significant difference in dose alterations and outcomes with EC-MPS compared with MMF.

Abbreviations:
GI: gastrointestinal; EC MPS, enteric-coated mycophenolate sodium; MMF: mycophenolate mofetil; GI: gastrointestinal; MPA: mycophenolic acid; BPAR: biopsy-proven acute rejection

References:
1. Gil-Vernet S, et al. Transplant Proc. 2007;39(7):2190-2193. 2. Salvadori M, et al. Am J Transplant. 2004;4(2):231-236. 3. Chan L, et al. Transplantation. 2008;81(9):1290-1297. 4. Sollinger HW, et al. Transplantation. 2010;89(4):446-451